LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and ...
Simulations Plus is benefiting from the growing use of computational tools in drug discovery, which would be boosted by the FDA Modernization Act 2.0. The biosimulation market is highly fragmented and ...
Hosted on MSN
Simulations Plus (SLP) Q3 2025 Earnings Transcript
Image source: The Motley Fool. Need a quote from one of our analysts? Email [email protected] Read More: Earn up to $845 cash back this year just by changing how you pay at Costco! Learn more here. A $77.2 ...
Simulations Plus, Inc.SLP was a big mover last session, as the company saw its shares rise nearly 6% on the day. Shares gained after the company reported higher earnings and revenues for the third ...
Simulations Plus is a software company that develops tools for modeling and simulation in the pharmaceutical, biotechnology, and chemical industries. In June 2024, Simulations Plus acquired ...
Simulations Plus faces soft revenue growth in the short term, due largely to macro conditions. The negatives appear to have been priced in, though, after a period of significant share price declines.
Simulations Plus, founded in 1996, has established itself as a key player in the bio-simulation market, second only to its larger competitor, Certara (NASDAQ:CERT). The company's business model is ...
Polen Capital Management, a value-driven, concentrated, long-term investment management firm, published its ‘Polen U.S. Small Company Growth’ fourth-quarter 2020 Investor Letter – a copy of which can ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results